Ocugen announces first patient dosed in Phase 2/3 GARDian3 trial for OCU410ST

Ocugen (OCGN) announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST-a modifier gene therapy candidate being developed for all Stargardt disease. “Dosing the first patient is an especially significant milestone and brings us closer to our goal of addressing the unmet medical need that exists for all Stargardt patients-100,000 in the U.S. and Europe and 1 million worldwide,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen.